Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GORDON A BROWN

Allopathic & Osteopathic Physicians Urology

NPI
1124192489
CMS profile
142359
Location
CHERRY HILL, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$87,265.72

120 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GORDON A BROWN

NPI 1124192489 · CMS profile ID 142359

Allopathic & Osteopathic Physicians / Urology

CHERRY HILL, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124192489?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GORDON A BROWN, NPI 1124192489, CMS profile ID 142359. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124192489?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). GORDON A BROWN, NPI 1124192489, CMS profile ID 142359. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124192489?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
GORDON A BROWN, NPI 1124192489, CMS profile ID 142359, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1124192489?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

120 matching records · $87,265.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 120 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–120 of 120.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Myriad Genetic Laboratories, Inc. $12.3005/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834575683 CMS
Janssen Biotech, Inc. $1,000.0005/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787876771 CMS
Janssen Biotech, Inc. $2.5005/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787876875 CMS
TOLMAR Pharmaceuticals, Inc. $2,275.0005/06/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836494027 CMS
Exelixis Inc. $1,980.0005/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838867251 CMS
Janssen Biotech, Inc. $14.4405/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787876869 CMS
Janssen Biotech, Inc. $1,000.0005/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787876787 CMS
Janssen Biotech, Inc. $1,000.0005/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787876791 CMS
Myovant Sciences Inc. $1,300.0004/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834945837 CMS
Astellas Pharma US Inc $13.8604/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821271535 CMS
AstraZeneca Pharmaceuticals LP $950.0004/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834334673 CMS
AstraZeneca Pharmaceuticals LP $700.0004/06/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834323247 CMS
Astellas Pharma US Inc $705.0003/31/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821271531 CMS
AstraZeneca Pharmaceuticals LP $475.0003/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834345357 CMS
Bayer HealthCare Pharmaceuticals Inc. $1,512.0003/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789103629 CMS
UROGEN PHARMA, INC. $17.7003/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826679521 CMS
Myovant Sciences Inc. $1,300.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834945835 CMS
Foundation Medicine, Inc. $14.6702/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799849499 CMS
Janssen Biotech, Inc. $1,000.0002/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787876761 CMS
AstraZeneca Pharmaceuticals LP $950.0001/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834335989 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $114,914.00 141
PY2020 $117,944.57 106
PY2021 $87,265.72 120
PY2022 $193,088.92 129
PY2023 $259,042.03 161
PY2024 $235,093.51 167
PY2025 $244,580.53 188

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $97,582.33 34
PY2024 Principal investigator $168,225.45 40
PY2023 Principal investigator $319,108.30 293
PY2022 Principal investigator $248,826.13 83
PY2021 Recipient $7,000.00 1
PY2021 Principal investigator $396,381.13 67
PY2020 Principal investigator $149,439.31 40
PY2019 Recipient $2,977.50 1
PY2019 Principal investigator $172,385.61 35

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

34 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,551.00 12/19/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411744
Principal investigator 1 AstraZeneca UK Limited $7,000.00 12/03/2025 Non-covered Recipient Entity
SUMMIT HEALTH BERKELEY HEIGHTS CAMPUS
a randomized,double blind,placebo controlled,phase third study of adjuvant saruparib AZD5305 in patients with bracam localized high risk prostate cancer receiving radiotherapy with aqndrogen deprivation therapy evo par prostate No dispute reported 06/30/2026 1185541958
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,551.00 11/14/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409602
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,551.00 11/14/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409616
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,551.00 11/14/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409748
Principal investigator 1 Sumitomo Pharma America, Inc. $7,494.00 11/05/2025 Non-covered Recipient Entity
SUMMIT MEDICAL GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654595
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 11/05/2025 Non-covered Recipient Entity
SUMMIT MEDICAL GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654770
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 11/05/2025 Non-covered Recipient Entity
SUMMIT MEDICAL GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654777
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 11/05/2025 Non-covered Recipient Entity
SUMMIT MEDICAL GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654900
Principal investigator 1 Sumitomo Pharma America, Inc. $25,045.00 11/05/2025 Non-covered Recipient Entity
SUMMIT MEDICAL GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176655010
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 11/05/2025 Non-covered Recipient Entity
SUMMIT MEDICAL GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176655073
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,720.15 10/15/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409994
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,720.15 08/28/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409200
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,720.15 08/28/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409344
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,720.15 08/28/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409372
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,720.15 08/28/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409406
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,720.15 08/28/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409516
Principal investigator 1 Novartis Pharmaceuticals Corporation $348.93 08/26/2025 Non-covered Recipient Entity
SUMMIT HEALTH ORTHOPEDICS AND SPORTS MEDICINE HACKENSACK
A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1190308222
Principal investigator 1 Sumitomo Pharma America, Inc. $1,244.00 08/01/2025 Non-covered Recipient Entity
SUMMIT MEDICAL GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641724
Principal investigator 1 Sumitomo Pharma America, Inc. $2,054.00 08/01/2025 Non-covered Recipient Entity
SUMMIT MEDICAL GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641728
Principal investigator 1 Sumitomo Pharma America, Inc. $5,382.00 07/09/2025 Non-covered Recipient Entity
SUMMIT MEDICAL GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176640282
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,720.15 06/04/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407838
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,720.15 06/04/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407948
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,720.15 06/04/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408018
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,720.15 06/04/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408108
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,720.15 06/04/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408126
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,720.15 06/04/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408148
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,720.15 06/04/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408162
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,720.15 06/04/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408322
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,720.15 06/04/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408480
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,720.15 06/04/2025 Non-covered Recipient Entity
Tristate Urologic Services Psc Inc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408506
Principal investigator 1 Sumitomo Pharma America, Inc. $2,563.00 05/07/2025 Non-covered Recipient Entity
SUMMIT MEDICAL GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176634297
Principal investigator 1 Sumitomo Pharma America, Inc. $12,500.00 04/09/2025 Non-covered Recipient Entity
SUMMIT MEDICAL GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632944
Principal investigator 1 Sumitomo Pharma America, Inc. $105.00 04/09/2025 Non-covered Recipient Entity
SUMMIT MEDICAL GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632949